CN1483018A - 那格列奈b型结晶的制造方法 - Google Patents
那格列奈b型结晶的制造方法 Download PDFInfo
- Publication number
- CN1483018A CN1483018A CNA018212999A CN01821299A CN1483018A CN 1483018 A CN1483018 A CN 1483018A CN A018212999 A CNA018212999 A CN A018212999A CN 01821299 A CN01821299 A CN 01821299A CN 1483018 A CN1483018 A CN 1483018A
- Authority
- CN
- China
- Prior art keywords
- nateglinide
- crystallization
- manufacture method
- crystal
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供包括在低温下将那格列奈(nateglinide)的溶剂化物湿润结晶干燥到溶剂消失之后使之结晶转变的工序的、制造实质上不含有H型结晶的那格列奈B型结晶的方法。根据此方法可以在工业规模上制造那格列奈B型结晶的单一结晶。
Description
发明领域
本发明涉及有效的糖尿病药物那格列奈(nateglinide)[化学名：N-(反式-4-异丙基环己基羰基)-D-苯基丙氨酸；N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine]的制造方法。更详细说，本发明涉及实质上不含有H型结晶的那格列奈B型结晶的制造方法。
背景技术
已经知道，那格列奈是一种有效的糖尿病治疗药物，口服显示优异的降血糖作用(特公平4-15221号公报)。
又，已经知道，那格列奈具有多种结晶形态，其中的H型结晶是有用的。然而，为了离析出H型结晶，就必须严格地控制晶析条件，很谨慎地进行晶析，存在难以晶析操作的问题(参见专利第2508949号)。
另一方面，其它结晶形态之一的B型结晶，具有在晶析时通过进行冷却晶析而可容易地制造的优点。然而，此B型结晶在制造阶段有可能转变成H型结晶，事实在工业规模制造那格列奈时，判明所得到的B型结晶中混入有H型结晶。作为药品使用的那格列奈，尽可能避免结晶多形的混入为好，如果可能的话，单一晶形为最好，因此希望开发可以提供只含有此B型结晶的医药制剂的、没有结晶多形混入的那格列奈B型结晶的制造方法。
发明内容
本发明的目的在于提供工业制造没有混入其它晶形的那格列奈B型结晶的方法。
本发明人以有效利用那格列奈B型结晶为目的进行研究的结果，发现通过选择那格列奈制造阶段的条件就可以以工业规模制造单一晶形的那格列奈B型结晶，至此完成了本发明。
即，本发明提供包括在低温下将那格列奈的溶剂化物湿润结晶干燥到溶剂消失之后使之结晶转变的工序的、实质上不含有H型结晶的那格列奈B型结晶的制造方法。
本发明提供，理想情况是，将含有由含那格列奈的溶液通过冷却晶析而析出得到的那格列奈水合物的溶剂化物在50℃以下的温度干燥到溶剂消失、溶剂化物实质上消除之后，加热至60℃～110℃，使之向B型结晶结晶转变的工序的、制造实质上不含有H型结晶的那格列奈B型结晶的方法。
实施发明的最佳方案
作为本发明所使用的那格列奈的溶剂化物湿润结晶，列举有，甲醇、乙醇和异丙醇等醇类、乙酸甲酯或乙酸乙酯等乙酸酯类、或水的溶剂化物。作为那格列奈的溶剂化物湿润结晶，通常使用醇合物和水合物等。在用乙醇合物的场合，例如通过在60％乙醇水中加入那格列奈并使其达到5重量％的浓度，在30℃左右溶解之后，把它冷却到10℃以下而可制备。
其中，水合物由于是在那格列奈的醇溶液、优选乙醇溶液中加入水，冷却到10℃以下而晶析出，所以通过分离它就可以容易得到，因此优选。
所得到的溶剂化物的湿润结晶，使之干燥到溶剂消失。此时的温度根据附着在结晶上的溶剂的种类和数量的不同而不同，但通常在60℃以下，优选在50℃以下为。温度的下限没有特别的限制，但是从经济观点考虑，通常在20℃以上进行。干燥通常在减压下为好，工业上尽可能提高减压度时以短时间完成干燥。
在低温的干燥继续到溶剂实质上消失为止，但没有必要完全消失，即使残留5重量％左右的溶剂，由于在结晶转变时也消失所以也没有问题。
所得到的干燥结晶通过加热到60℃～110℃、优选70℃～100℃，使其转变成B型结晶。结晶转变通常进行0.5～48小时为好，更优选1～24小时。
B型结晶中的H型结晶通过使用DSC而可分析。那格列奈B型结晶在用DSC测定时，检测不到H型结晶为好。
湿润状态的那格列奈溶剂化物结晶干燥的场合，在实验室规模的小规模的情况下，由于分离结晶时的残留溶剂量少，并且达到干燥器的最高减压的速度快，所以即使从初期阶段提高干燥温度也没有大的问题，但在工业规模下，例如，平均1次制造5kg以上的情况下，在从晶析液分离的结晶中残留的溶剂量多，并且干燥时到达最高减压度的时间比较长，因此，通过使用本发明的方法制造不含有H型结晶的B型结晶成为可能。
下面通过实施例来更具体地说明本发明，但是本发明并不限于这些实施例。
实施例1
把24.5kg的那格列奈H型结晶加入到360L乙醇中，在室温下搅拌使之溶解。向其中加入240L水，在确认溶解之后，冷却到5℃，再在5℃下熟化1小时。分离析出的结晶，得到湿结晶43.0kg。把它放在盘式干燥器中，于45℃干燥24小时(水分含量约1重量％)，再在90℃加热12小时，使之结晶转变，得到干燥结晶13.3kg。测定此结晶的DSC的结果，检测出了B型结晶特有的峰(熔点约130℃)，但没有检测出H型结晶特有的峰(熔点约139℃)，因此结论是所得到的结晶只是B型结晶，实质上不含有H型结晶。比较例1
把37.0kg的那格列奈H型结晶加入到540L乙醇中，在室温下搅拌使之溶解。向其中加入360L水，在确认溶解之后，冷却到5℃，再在5℃下熟化1小时。分离析出的结晶，得到湿结晶46.7kg。把它放在锥形干燥器中，于30℃干燥3小时(水分含量约10重量％)，再在90℃加热12小时，使之结晶转变，得到干燥结晶25.9kg。测定此结晶的DSC的结果，除了B型结晶之外，还观察到H型结晶的峰。比较例2
把37.0kg的那格列奈H型结晶加入到540L乙醇中，在室温下搅拌使之溶解，向其中加入360L水，在确认溶解之后，冷却到5℃，再在5℃下熟化1小时。分离析出的结晶，得到湿结晶44.5kg。把它放在锥形干燥器中，于30℃干燥3小时(水分含量约10重量％)，再在90℃加热15小时，使之结晶转变，得到干燥B型结晶26.6kg。测定此结晶的DSC的结果，除了B型结晶之外，还观察到H型结晶的峰。
通过使用本发明的条件，以工业规模制造不存在其它晶型的那格列奈B型结晶成为可能，廉价地提供以单一那格列奈结晶的形式含有那格列奈B型结晶的医药制剂成为可能。
Claims (9)
1.一种实质上不含有H型结晶的那格列奈B型结晶的制造方法，包括在低温下将那格列奈的溶剂化物湿润结晶干燥到溶剂消失之后使之结晶转变。
2.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中所得到的那格列奈B型结晶在用DSC测定的情况下检测不到H型结晶。
3.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中在50℃以下的温度进行干燥。
4.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中进行干燥直到实质上溶剂消失为止。
5.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中前述溶剂化物湿润结晶是水合物。
6.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中加热到60～110℃来进行结晶转变。
7.根据权利要求项1所述的那格列奈B型结晶的制造方法，其中，那格列奈溶剂化物湿润结晶的低温干燥和结晶转变这两个工序是在工业规模下进行的工序。
8.一种实质上不含有H型结晶的那格列奈B型结晶的制造方法，包括将含有由含那格列奈的溶液通过冷却晶析而析出得到的那格列奈水合物的溶剂化物在50℃以下的温度干燥到溶剂消失、溶剂化物实质上消除之后，加热至60～110℃，使之向B型结晶结晶转变。
9.根据权利要求项8所述的那格列奈B型结晶的制造方法，其中所得到的那格列奈B型结晶在用DSC测定的情况下检测不到H型结晶。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000324375 | 2000-10-24 | ||
| JP324375/2000 | 2000-10-24 | ||
| JP324375/00 | 2000-10-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1483018A true CN1483018A (zh) | 2004-03-17 |
| CN100422143C CN100422143C (zh) | 2008-10-01 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018212999A Expired - Fee Related CN100422143C (zh) | 2000-10-24 | 2001-10-23 | 那格列奈b型结晶的制造方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030229249A1 (zh) |
| EP (1) | EP1334964B1 (zh) |
| JP (1) | JP4225057B2 (zh) |
| KR (1) | KR100810930B1 (zh) |
| CN (1) | CN100422143C (zh) |
| AT (1) | ATE370115T1 (zh) |
| AU (1) | AU2001296001A1 (zh) |
| BR (1) | BR0114846A (zh) |
| CA (1) | CA2426745C (zh) |
| CY (1) | CY1106839T1 (zh) |
| DE (1) | DE60130014T2 (zh) |
| DK (1) | DK1334964T3 (zh) |
| ES (1) | ES2288997T3 (zh) |
| MX (1) | MXPA03003575A (zh) |
| PT (1) | PT1334964E (zh) |
| RU (1) | RU2275354C2 (zh) |
| TW (1) | TWI293290B (zh) |
| WO (1) | WO2002034713A1 (zh) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1283054A4 (en) * | 2000-03-17 | 2006-04-12 | Ajinomoto Kk | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF |
| PT1334963E (pt) * | 2000-10-18 | 2007-09-20 | Ajinomoto Kk | Processo para a produção de cristais de nateglinida |
| CN1273442C (zh) * | 2000-10-18 | 2006-09-06 | 味之素株式会社 | 酰基苯丙氨酸的制备方法 |
| WO2002040010A1 (fr) * | 2000-10-24 | 2002-05-23 | Ajinomoto Co.,Inc. | Preparations de medicament contenant du nateglinide |
| RU2271805C2 (ru) * | 2000-10-24 | 2006-03-20 | Адзиномото Ко., Инк. | Препарат, содержащий натеглинид |
| AU2003236243A1 (en) * | 2002-04-15 | 2003-10-27 | Ajinomoto Co., Inc. | Novel nateglinide crystal |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| AU2003253971A1 (en) * | 2002-07-18 | 2004-02-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| ATE349418T1 (de) * | 2003-11-26 | 2007-01-15 | A M S A Anonima Materie Sint E | Verfahren zur herstellung von nateglinidin der b- form |
| EP1656339A1 (en) * | 2004-05-07 | 2006-05-17 | Teva Pharmaceutical Industries Ltd | Polymorphic forms of nateglinide |
| WO2005110395A1 (en) * | 2004-05-19 | 2005-11-24 | University Of South Carolina | System and device for magnetic drug targeting with magnetic drug carrier particles |
| US20080096970A1 (en) * | 2004-05-20 | 2008-04-24 | Sundaram Venkataraman | Stable Nateglinide Form B Compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| KR20070102694A (ko) * | 2005-01-31 | 2007-10-19 | 아지노모토 가부시키가이샤 | 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| CA2802455A1 (en) | 2010-06-14 | 2011-12-22 | Cipla Limited | A process for the preparation of nateglinide |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
| US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| AU2013257708A1 (en) * | 2012-05-08 | 2014-12-04 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
| AU2014414316B2 (en) | 2014-10-27 | 2020-04-09 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| JP6679616B2 (ja) | 2015-01-06 | 2020-04-22 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 炎症及び疼痛の治療のための組成物及び方法 |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| DE10199058I2 (de) | 1991-07-30 | 2006-04-27 | Alcm Co | Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| ES2257772T3 (es) * | 1996-11-15 | 2006-08-01 | Ajinomoto Co., Inc. | Preparacion de nateglinida en comprimidos. |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| RU2002120498A (ru) * | 1999-12-28 | 2004-04-10 | Адзиномото Ко., Инк. (Jp) | Противодиабетический препарат для перорального введения |
| EP1283054A4 (en) * | 2000-03-17 | 2006-04-12 | Ajinomoto Kk | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF |
| CN1273442C (zh) * | 2000-10-18 | 2006-09-06 | 味之素株式会社 | 酰基苯丙氨酸的制备方法 |
| PT1334963E (pt) * | 2000-10-18 | 2007-09-20 | Ajinomoto Kk | Processo para a produção de cristais de nateglinida |
| RU2271805C2 (ru) * | 2000-10-24 | 2006-03-20 | Адзиномото Ко., Инк. | Препарат, содержащий натеглинид |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active IP Right Cessation
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja active IP Right Grant
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60130014D1 (de) | 2007-09-27 |
| WO2002034713A1 (fr) | 2002-05-02 |
| EP1334964B1 (en) | 2007-08-15 |
| CN100422143C (zh) | 2008-10-01 |
| CA2426745C (en) | 2009-09-15 |
| EP1334964A1 (en) | 2003-08-13 |
| TWI293290B (zh) | 2008-02-11 |
| US7544834B2 (en) | 2009-06-09 |
| ES2288997T3 (es) | 2008-02-01 |
| US20070232829A1 (en) | 2007-10-04 |
| JPWO2002034713A1 (ja) | 2004-03-04 |
| BR0114846A (pt) | 2004-02-25 |
| JP4225057B2 (ja) | 2009-02-18 |
| PT1334964E (pt) | 2007-09-20 |
| DE60130014T2 (de) | 2008-05-08 |
| KR100810930B1 (ko) | 2008-03-10 |
| ATE370115T1 (de) | 2007-09-15 |
| CY1106839T1 (el) | 2012-05-23 |
| EP1334964A4 (en) | 2005-09-28 |
| MXPA03003575A (es) | 2003-07-14 |
| US20030229249A1 (en) | 2003-12-11 |
| CA2426745A1 (en) | 2003-04-23 |
| KR20030059212A (ko) | 2003-07-07 |
| RU2275354C2 (ru) | 2006-04-27 |
| AU2001296001A1 (en) | 2002-05-06 |
| DK1334964T3 (da) | 2007-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100422143C (zh) | 那格列奈b型结晶的制造方法 | |
| O'Sullivan et al. | Application of in situ FBRM and ATR-FTIR to the monitoring of the polymorphic transformation of D-mannitol | |
| Simon et al. | Diastereomeric salt crystallization of chiral molecules v ia sequential coupled‐B atch operation | |
| CN102660621A (zh) | 一种改进的酶法制备阿莫西林的方法 | |
| CN101070287A (zh) | 从二甲戊乐灵中脱去n－亚硝基二甲戊乐灵的方法 | |
| CN103896862A (zh) | 一种吉非替尼Form 1晶型新的制备方法 | |
| CN109053473B (zh) | 大规模生产3-氨基-2-丁烯酸肉桂酯以及西尼地平的工艺 | |
| JP5827684B2 (ja) | ２−［３−シアノ−４−（２−ｉ−ブトキシ）フェニル］−４−メチル−５−チアゾール−カルボン酸（フェブキソスタット）の結晶形Ａを調製するための方法 | |
| EP1722222A1 (en) | Method of determining impurity in acrylic acid | |
| EP3210962B1 (fr) | Compositions riches en cristaux de mannitol sous forme delta | |
| CN105566296A (zh) | 一种制备达比加群酯酰胺化杂质的方法 | |
| CN105859646A (zh) | 一种缬沙坦的精制方法 | |
| JPH06116146A (ja) | 製 剤 | |
| WO2009144407A1 (fr) | Sels de quinoleines 2-substituees | |
| US5874614A (en) | Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate | |
| CN104109108A (zh) | α-位季碳的α,β-二胺酸衍生物及其共催化制备方法和应用 | |
| CN104058998B (zh) | α-胺基，δ-羟基己二酸衍生物及其制备方法和应用 | |
| BR112015012175B1 (pt) | processo para preparação de monômeros de ácido fosfônico | |
| WO2023209033A1 (en) | Method for crystallizing tapentadol intermediate, tapentadol intermediate of high purity, method of making tapentadol and tapentadol of high purity | |
| CN100429202C (zh) | 一种无定形氟伐他汀钠的制备方法 | |
| Hino et al. | The influence of a small amount of maleic acid on crystal deposition phenomena of methacrylic acid in melt crystallization | |
| Wantha | Project Title: A Study into the Effectiveness of Crystallization Process in Purification of Active Pharmaceutical Ingredients | |
| Bickel | The Racemization of an Optically Active Acid and its Methyl Ester | |
| Madho et al. | Preliminary assessment of selected South African ball-milled slurries. | |
| CN106866519A (zh) | 一种罗氟司特晶型化合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081001 Termination date: 20131023 |